£113.76

Springer Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance: From Basic to Clinical Research

Price data last checked 47 day(s) ago - refreshing...

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

This is the most expensive it has ever been. Walk away.

£114 today · previous high £114 · all-time low £113

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey
↓ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 44 days • 44 data points (No recent data available)

Historical
Generating forecast...
£113.76 £113.20 £113.32 £113.44 £113.57 £113.69 £113.81 05 April 2026 15 April 2026 26 April 2026 07 May 2026 18 May 2026

Price Distribution

Price distribution over 44 days • 2 price levels

Days at Price
Current Price
32 days 12 days · current 0 8 16 24 32 £113 £114 Days at Price

Price Analysis

Most common price: £113 (32 days, 72.7%)

Price range: £113 - £114

Price levels: 2 different prices over 44 days

Description

Describes the ability of a series of endocrine-derived compounds, i.e. CHRH, LHRH, somatostatin, anti-androgens, and aromatase inhibitors to exert a direct anti-neoplastic activity or to potentiate the activity of traditional chemotherapeutic agents on neuroendocrine and solid tumors. In addition, a new class of potent GH-releasers, GSHs/Ghrelin, endowed with important endocrine and extra-endcocrine action, is presented. Therefore, in addition to traditional chemotherapy, characterized by high toxicity and non-selective action on tumoral cells, the reader can find a new approach with more selective, less cytotoxic endocrine derived compounds.

Product Specifications

Format
paperback
Domain
Amazon UK
Publication Date
08 October 2012
Listed Since
06 December 2012

Barcode

No barcode data available

Similar Products You Might Like

Endocrine Therapies in Breast and Prostate Cancer: 39 (Cancer Treatment and Research, 39)
83% match

Endocrine Therapies in Breast and Prostate Cancer: 39 (Cancer Treatment and Research, 39)

Springer

£113.76 26 May 2026
Hormone Receptors in Breast Cancer: 147 (Cancer Treatment and Research, 147)
82% match

Hormone Receptors in Breast Cancer: 147 (Cancer Treatment and Research, 147)

Springer

£80.64 18 May 2026
Novel Apoptotic Regulators in Carcinogenesis
80% match

Novel Apoptotic Regulators in Carcinogenesis

Springer

£124.17 12 Jun 2026
Hormones and Cancer: 138 (Advances in Experimental Medicine and Biology, 138)
80% match

Hormones and Cancer: 138 (Advances in Experimental Medicine and Biology, 138)

Springer

£77.33 26 May 2026
Growth Hormone Secretagogues: Basic Findings and Clinical Implications
80% match

Growth Hormone Secretagogues: Basic Findings and Clinical Implications

Elsevier

£110.00 30 Jun 2026
Human Growth Hormone
80% match

Human Growth Hormone

Springer

£74.40 25 May 2026
Resistance to Tyrosine Kinase Inhibitors (Resistance to Targeted Anti-Cancer Therapeutics)
80% match

Resistance to Tyrosine Kinase Inhibitors (Resistance to Targeted Anti-Cancer Therapeutics)

Springer

£107.98 06 Jun 2026
Resistance to Tyrosine Kinase Inhibitors (Resistance to Targeted Anti-Cancer Therapeutics)
80% match

Resistance to Tyrosine Kinase Inhibitors (Resistance to Targeted Anti-Cancer Therapeutics)

Springer

£107.98 24 May 2026
Nutraceuticals and Cancer
80% match

Nutraceuticals and Cancer

Springer

£113.76 25 May 2026
Hormonal Carcinogenesis: Proceedings of the First International Symposium
80% match

Hormonal Carcinogenesis: Proceedings of the First International Symposium

Springer

£77.72 03 Jun 2026
Sex-steroid Interactions with Growth Hormone (Serono Symposia)
80% match

Sex-steroid Interactions with Growth Hormone (Serono Symposia)

Springer

£111.50 20 May 2026
The Rho GTPases in Cancer
80% match

The Rho GTPases in Cancer

Springer

£107.98 03 Jun 2026
Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models
80% match

Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models

Springer

£74.57 05 Jun 2026
Pathobiology of Human Germ Cell Neoplasia: 123 (Recent Results in Cancer Research, 123)
80% match

Pathobiology of Human Germ Cell Neoplasia: 123 (Recent Results in Cancer Research, 123)

Springer

£113.93 06 Jun 2026
Endocrine Therapy of Breast Cancer VI (ESO Monographs)
80% match

Endocrine Therapy of Breast Cancer VI (ESO Monographs)

Springer

£76.38 01 Jun 2026
Cancer Genetics and Therapeutics: Focus on Phytochemicals
80% match

Cancer Genetics and Therapeutics: Focus on Phytochemicals

Springer

£74.87 24 May 2026
Textbook of Energy Balance, Neuropeptide Hormones, and Neuroendocrine Function
80% match

Textbook of Energy Balance, Neuropeptide Hormones, and Neuroendocrine Function

Springer

£65.57 20 May 2026
Hodgkin's and Non-Hodgkin's Lymphoma: 131 (Cancer Treatment and Research, 131)
80% match

Hodgkin's and Non-Hodgkin's Lymphoma: 131 (Cancer Treatment and Research, 131)

Springer

£81.58 06 Jun 2026
Bioactive Essential Oils and Cancer
80% match

Bioactive Essential Oils and Cancer

Springer

£107.98 19 May 2026
Retinoids in Oncology (ESO Monographs)
80% match

Retinoids in Oncology (ESO Monographs)

Springer

£113.93 24 May 2026
Regulation of Carcinogenesis, Angiogenesis and Metastasis by the Proprotein Convertases (PC's): A New Potential Strategy in Cancer Therapy
79% match

Regulation of Carcinogenesis, Angiogenesis and Metastasis by the Proprotein Convertases (PC's): A New Potential Strategy in Cancer Therapy

Springer

£113.76 09 Jun 2026
Pharmaceutical Perspectives of Cancer Therapeutics
79% match

Pharmaceutical Perspectives of Cancer Therapeutics

Springer

£179.99 06 Jun 2026
Progestogens in Obstetrics and Gynecology
79% match

Progestogens in Obstetrics and Gynecology

Springer

£107.98 01 Jun 2026
Familial Endocrine Cancer Syndromes: Navigating the Transition of Care for Pediatric and Adolescent Patients
79% match

Familial Endocrine Cancer Syndromes: Navigating the Transition of Care for Pediatric and Adolescent Patients

Springer

£73.10 20 May 2026